Seymour L - Search Results

1

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K. Garcia-Carbonero R, et al. Among authors: seymour l. J Immunother Cancer. 2017 Sep 19;5(1):71. doi: 10.1186/s40425-017-0277-7. J Immunother Cancer. 2017. PMID: 28923104 Free PMC article. Clinical Trial.

2

Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus.

Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, Hermiston T, Ulbrich K, Fisher KD, Seymour LW. Green NK, et al. Among authors: seymour lw. Gene Ther. 2004 Aug;11(16):1256-63. doi: 10.1038/sj.gt.3302295. Gene Ther. 2004. PMID: 15215884

3

Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.

Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, Phipps S, Hale S, Mautner V, Seymour LW, Fisher KD. Lyons M, et al. Mol Ther. 2006 Jul;14(1):118-28. doi: 10.1016/j.ymthe.2006.01.003. Epub 2006 Mar 31. Mol Ther. 2006. PMID: 16580883 Free article.

4

Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.

Carlisle RC, Briggs SS, Hale AB, Green NK, Fisher KD, Etrych T, Ulbrich K, Mautner V, Seymour LW. Carlisle RC, et al. Among authors: seymour lw. Gene Ther. 2006 Nov;13(22):1579-86. doi: 10.1038/sj.gt.3302814. Epub 2006 Jun 29. Gene Ther. 2006. PMID: 16810196

5

Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins.

Stevenson M, Hale AB, Hale SJ, Green NK, Black G, Fisher KD, Ulbrich K, Fabra A, Seymour LW. Stevenson M, et al. Among authors: seymour lw. Cancer Gene Ther. 2007 Apr;14(4):335-45. doi: 10.1038/sj.cgt.7701022. Epub 2007 Jan 19. Cancer Gene Ther. 2007. PMID: 17235355

6

Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy.

Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Fisher KD, et al. J Drug Target. 2007 Aug-Sep;15(7-8):546-51. doi: 10.1080/10611860701501014. J Drug Target. 2007. PMID: 17671901

7

Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.

Morrison J, Briggs SS, Green N, Fisher K, Subr V, Ulbrich K, Kehoe S, Seymour LW. Morrison J, et al. Mol Ther. 2008 Feb;16(2):244-51. doi: 10.1038/sj.mt.6300363. Epub 2007 Dec 11. Mol Ther. 2008. PMID: 18071336 Free article.

8

Cellular carriers or free viruses?

Seymour LW, Cawood R, Fisher KD. Seymour LW, et al. Curr Opin Mol Ther. 2008 Aug;10(4):321-2. Curr Opin Mol Ther. 2008. PMID: 18683095 No abstract available.

9

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y, Seymour LW. Bazan-Peregrino M, et al. Among authors: seymour lw. Hum Gene Ther. 2008 Sep;19(9):873-86. doi: 10.1089/hum.2008.047. Hum Gene Ther. 2008. PMID: 18710328

10

Quantification of siRNA using competitive qPCR.

Liu WL, Stevenson M, Seymour LW, Fisher KD. Liu WL, et al. Nucleic Acids Res. 2009 Jan;37(1):e4. doi: 10.1093/nar/gkn903. Epub 2008 Nov 12. Nucleic Acids Res. 2009. PMID: 19004870 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

564 results

Search Page

Filters